Nanosystems for gene therapy targeting brain damage caused by viral infections

Mater Today Bio. 2022 Dec 17:18:100525. doi: 10.1016/j.mtbio.2022.100525. eCollection 2023 Feb.

Abstract

Several human pathogens can cause long-lasting neurological damage. Despite the increasing clinical knowledge about these conditions, most still lack efficient therapeutic interventions. Gene therapy (GT) approaches comprise strategies to modify or adjust the expression or function of a gene, thus providing therapy for human diseases. Since recombinant nucleic acids used in GT have physicochemical limitations and can fail to reach the desired tissue, viral and non-viral vectors are applied to mediate gene delivery. Although viral vectors are associated to high levels of transfection, non-viral vectors are safer and have been further explored. Different types of nanosystems consisting of lipids, polymeric and inorganic materials are applied as non-viral vectors. In this review, we discuss potential targets for GT intervention in order to prevent neurological damage associated to infectious diseases as well as the role of nanosized non-viral vectors as agents to help the selective delivery of these gene-modifying molecules. Application of non-viral vectors for delivery of GT effectors comprise a promising alternative to treat brain inflammation induced by viral infections.

Keywords: Brain inflammation; Dendrimers; Gene therapy; Inorganic nanoparticles; Lipid nanosystems; Polymeric nanoparticles; Viral infection; iRNA.

Publication types

  • Review